glp-1 agonists blindness risk Zepbound Lawsuit [2026 Update] Mapping the effectiveness and risks
Description
J Pharmacol Sci
![glp-1 agonists blindness risk Zepbound Lawsuit [2026 Update] Mapping the effectiveness and risks](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-024-03412-w/MediaObjects/41591_2024_3412_Fig1_HTML.png)
doi: 10.1038/ijo.2013.73 22 AsmarMAsmarASimonsenLGasbjergLSSparre-UlrichAHRosenkildeMMet al
![glp-1 agonists blindness risk Zepbound Lawsuit [2026 Update] Mapping the effectiveness and risks](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/905e/12340654/21076ad9b956/jamanetwopen-e2526321-g001.jpg)
There was no difference in the risk of CV death when GLP-1RA were compared with SGLT-2 inhibitors
![glp-1 agonists blindness risk Zepbound Lawsuit [2026 Update] Mapping the effectiveness and risks](https://i.ytimg.com/vi/4GjlRv2m4aU/hqdefault.jpg)
Boost digestion
![glp-1 agonists blindness risk Zepbound Lawsuit [2026 Update] Mapping the effectiveness and risks](https://www.reviewofoptometry.com/CMSImagesContent/2025/03/RO/RO_0325_059_table.jpg)